OncoMatch/Clinical Trials/NCT04746209
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Is NCT04746209 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Alpha/Beta T-cell and B-cell depleted HCT and Blinatumomab for b-cell acute lymphoblastic leukemia.
Treatment: Alpha/Beta T-cell and B-cell depleted HCT · Blinatumomab — This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Demographics
Prior therapy
Must have received: hematopoietic cell transplant
Patients must have an available unrelated or haploidentical donor
Cannot have received: immunotherapy (blinatumomab)
Exception: allowed if at least 42 days after completion
At least 42 days after the completion of any type of immunotherapy aside from blinatumomab (e.g. tumor vaccines or CAR T-cell therapy).
Cannot have received: radiation therapy
Exception: ≥ 90 days must have elapsed if prior TBI, cranial or craniospinal XRT
Cranial or craniospinal XRT is prohibited during protocol therapy. ≥ 90 days must have elapsed if prior TBI, cranial or craniospinal XRT
Lab requirements
Kidney function
creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73m2
Liver function
ALT < 5 x upper limit of normal (ULN) and total bilirubin ≤ 3 mg/dL
Cardiac function
left ventricular ejection fraction ≥ 40% by ECHO/MUGA
Renal: creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73m2 Hepatic: ALT < 5 x upper limit of normal (ULN) and total bilirubin ≤ 3 mg/dL Cardiac: left ventricular ejection fraction ≥ 40% by ECHO/MUGA Pulmonary: No evidence of dyspnea at rest. No supplemental oxygen requirement. If measured, carbon monoxide diffusion capacity (DLCO) > 50%. Central Nervous System: Based on clinical exam, no concern for/evidence of active CNS infection. Patients with fully treated prior CNS infections are eligible. Patients with seizure disorders may be enrolled if seizures are well-controlled on anticonvulsant therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04746209 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages